Computational mapping of antibody-receptor energy landscapes to predict membrane internalization

Pablo Llombart[†],[1,2,3,4] Cristina Nieto-Jiménez[†],[5] Atanasio Pandiella,[6] Alberto Ocana,[7,2,5,4,a)] and Jorge R. Espinosa[1,2,3,4,b)]

[1)] *Department of Physical Chemistry, Universidad Complutense de Madrid, Av. Complutense s/n, Madrid 28040, Spain*

[2)] *Instituto Pluridisciplinar, Universidad Complutense de Madrid, P.º de Juan XXIII, 1, Moncloa - Aravaca, 28040 Madrid, Spain*

[3)] *Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK*

[4)] *C-Therapeutics, TMC3 Elix Park 1885 Old Spanish Trl, Houston, TX 77039 United States*

[5)] *Experimental Therapeutics CRIS Cancer Unit, Hospital Clinico San Carlos and IdSCC and CIBERONC, Madrid, Spain*

[6)] *Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC) and Centro de Investigación Biomédica en Red–Cáncer (CIBERONC), 37007 Salamanca, Spain*

[7)] *Cátedra INTHEOS-START-CEU de Oncología de precisión, Facultad de Medicina, Universidad San Pablo-CEU, Montepríncipe, 28660 Boadilla del Monte, Madrid, Spain*

(Dated: 14 March 2026)

Antibody internalization is a critical property for the development of antibody–drug conjugates and targeted therapeutics, yet antibody discovery pipelines typically prioritize binding affinity rather than functional internalization. Here we show that molecular dynamics simulations can map the binding energy landscape between antibody clones and the membrane-proximal receptor JAM-A, enabling computational predictions of tumor cell internalization. Using the sequences of newly generated anti–JAM-A monoclonal antibodies (mABs), we perform atomistic potential-of-mean force simulations to evaluate the binding free energy to the JAM-A receptor and their interaction fingerprint at residue-level resolution. We find that internalizing mAB clones exhibit a unique membrane-oriented contact topology that promotes cooperative receptor–receptor interactions, lowering the energetic barrier for early endocytic events. Reconstruction of the receptor binding energy landscape further reveals that electrostatic interactions between charged residues and multivalent cation-π and polar interactions correlate with successful mAB internalization in ovarian cancer cells. In contrast, strong binding affinity of the fragment antigen-binding domain correlates with poor internalization. Together, our results establish molecular dynamics–guided clonal selection as a predictive framework for optimizing internalizing therapeutic antibodies and provide mechanistic insight into how antibody binding reshapes membrane-proximal receptor energetics to drive endocytosis.

I. INTRODUCTION

Antibody–drug conjugates (ADCs) have reshaped the therapeutic landscape of oncology by enabling the intracellular delivery of cytotoxic agents to tumor cells[1,2]. Since the clinical introduction of Gemtuzumab ozogamicin and subsequent approvals such as Trastuzumab emtansine and Trastuzumab deruxtecan[3], ADC development has primarily focused on three engineering axes: antigen selection, followed by linker and payload optimization[4,5]. Despite substantial chemical and biological innovation, the clinical efficacy of ADCs remains constrained by the selective expression of tumor-associated antigens (TAAs), payload-related off-tumor toxicities, and resistance mechanisms[6–8]. The identification of highly specific TAAs continues to represent a major bottleneck, as high differential expression between tumor and normal tissues is considered advantageous for successful ADC development[1,9]. Likewise, linker optimization and payload design critically influence intracellular drug release and bystander effects, thereby improving the efficacy and safety profile of ADCs[2,10].

A central yet underexplored determinant of ADC efficacy is the internalization of the antibody–drug conjugate following antigen binding. Importantly, internalization is not a simple extension of binding affinity to the target antigen. Although antibody discovery pipelines prioritize high-affinity clones against tumor-associated antigens (TAAs), efficient intracellular trafficking strongly depends on a complex interplay of multivalency, receptor clustering, membrane organization, and interfacial energetics that are largely dictated by the properties of the target receptor[11]. Clinical experience illustrates this distinction. Antibodies directed against HER2, such as trastuzumab, bind with high affinity yet induce relatively slow receptor internalization and substantial recycling[12]. HER2-directed ADCs includ-

[a)] Electronic mail: alberto.ocana@salud.madrid.org

[b)] Electronic mail: jorgerene@ucm.es;

[†] These authors contributed equally

ing trastuzumab emtansine and trastuzumab deruxtecan achieve clinical efficacy despite these intrinsic trafficking constraints, relying on optimized linker chemistry, drug-to-antibody ratio (DAR), and payload permeability to compensate for moderate cellular uptake[13,14]. Conversely, ADCs such as sacituzumab govitecan leverage high receptor density and multivalent engagement to promote clustering-dependent endocytosis[15].

A critical limitation in current clonal selection strategies is the reliance on static affinity metrics, which poorly predict whether a given antibody will be internalized after receptor engagement[16]. Efficient intracellular delivery requires that antibodies not only bind their target antigen but also induce productive conformational rearrangements and receptor clustering that facilitate endocytosis[17]. Mapping the dynamic interfacial energy landscape of antibody–antigen complexes provides a route to identify clones predisposed to generate favorable contact networks and mechanically stimulate internalization. Antibody multivalency introduces an additional level of complexity: each heavy and light chain can engage antigen epitopes in multiple geometries, creating diverse binding modes that differentially modulate receptor organization and downstream trafficking. Such multivalent interactions can enhance avidity, promote cooperative receptor clustering, and generate energetically distinct interfaces that govern internalization kinetics[11,12,18]. Importantly, the impact of these interactions also depends on the receptor family involved. Distinct receptor classes—including receptor tyrosine kinases, immune receptors, and G-protein–coupled receptors—possess different internalization motifs and trafficking pathways that influence how antibody-induced clustering translates into endocytosis and intracellular routing[19]. Capturing these effects therefore requires a dynamic, ensemble-based framework that accounts for both the conformational plasticity of the antibody and the topology of the antigenic surface.

At the molecular level, antibodies and ADCs behave as dynamic conformational ensembles rather than static binding entities[20,21]. Sequence variation, chemical conjugation, and environmental context reshape conformational distributions and interfacial electrostatics, with direct consequences for tumor targeting and intracellular trafficking[9]. Hydrophobic payloads can further modulate membrane interactions and cellular uptake, while simultaneously increasing the risk of aggregation and off-target effects[22,23]. In that respect, computational biophysics approaches, including atomistic molecular dynamics (MD) simulations and chemically accurate coarse-grained models[24–26], provide a framework to resolve these dynamic and multiscale phenomena beyond sequence-centric or static structural descriptions.

Here we propose that antibody internalization can be rationalized by reconstructing the binding energy landscape governing antibody–receptor engagement. Using atomistic molecular dynamics (MD) simulations, we analyze a set of newly generated monoclonal antibodies (mABs) targeting Junctional adhesion molecule A (JAM-A), a tight junction-associated receptor dysregulated in epithelial malignancies. JAM-A is a transmembrane protein composed of a single transmembrane helix and two extracellular Ig-like domains that mediate homophilic and heterophilic interactions at cell–cell junctions. These extracellular domains constitute the primary recognition sites for antibody binding, making JAM-A a suitable target for selective antibody-mediated delivery in tumor cells. Rather than ranking different mAB clones solely by binding affinity, we map clonal intermolecular contact fingerprints, quantify dominant energetic hubs, and resolve receptor–receptor interaction networks that emerge upon antibody binding to the receptor. We demonstrate that internalizing and non-internalizing clones, exhibit different binding properties and generate qualitatively distinct interfacial topologies. Internalizing clones are more labile and display multivalent binding modes which may ultimately drive cooperative receptor clustering, thereby lowering the effective energetic barriers associated with early endocytic events. Importantly, these computational predictions are experimentally validated through quantitative immunofluorescence internalization assays in tumor cells, establishing a direct correlation between predicted binding modes, and their corresponding energies, and cellular uptake behavior.

In this work, we show that MD–guided clonal selection can provide a predictive scoring for engineering tumor-internalizing antibodies, and ultimately enable the optimization and further development of next-generation ADCs. These results support a conceptual shift in antibody discovery toward using computational biophysical approaches to guide the selection of lead candidates, revealing that internalization propensity is encoded in dynamic, multiple binding modes rather than exclusively binding affinity. To provide a comprehensive characterization of the anti–JAM-A antibody system, our results are organized into sequential analyses spanning computational prediction, energetic evaluation, experimental validation, and mechanistic interpretation. First, we describe our computational framework, integrating sequence analysis, structure prediction using ColabFold[27–31], and atomistic MD simulations of antibody–antigen complexes. Using Umbrella Sampling calculations[32], we quantify the binding free energy of the different clones with the antigen. Moreover, we reveal a detailed mapping of the most energetically significant residue–residue interactions across each mAB clone. These energetic fingerprints enable quantitative scoring of antibody clones and allow correlation of computational predictions with experimental immunofluorescence measurements of cellular internalization. Finally, we explore multiple antibody binding modes arising from multivalency, and propose a mechanistic model for anti–JAM-A antibody internalization.

II. RESULTS AND DISCUSSIONS

A. An MD-based computational framework for clonal selection

To establish a physics-based framework for clonal evaluation, we implemented a multistep computational pipeline integrating sequence analysis, structural prediction, and all-atom MD simulations. We first analyzed the sequences of rabbit mABs targeting JAM-A (Fig. 1A). Classification of residues according to their physicochemical properties revealed distinct distributions of charged *vs.* hydrophobic amino acids within the complementarity-determining regions (CDRs), suggesting potential differences between the binding topology of the different clones. This sequence-level analysis provided us the initial basis for anticipating functional diversity beyond binding affinity measurements alone.

Subsequently, high-confidence structural models were generated. The predicted antibody structures displayed well-resolved ordered regions and flexible CDR loops, with per-residue predicted Local Distance Difference Test (pLDDT) scores indicating high structural reliability across the variable antibody domains (Fig. 1B). In parallel, the JAM-A ectodomain model was generated, exhibiting a stable β-strand-rich architecture consistent with immunoglobulin-like folds. Importantly, the predicted antibody–antigen complexes revealed spatial convergence of the six CDR loops toward a defined epitope region, establishing the structural context for intermolecular binding analysis. Although static structural prediction provides a geometrically optimized initial binding configuration (Fig. 1C), it does not capture conformational plasticity or transient intermolecular interactions. Therefore, we performed MD simulations of the antibody–JAM-A complex with the all-atom Amber99sb force field[33] in explicit solvent to resolve the time-dependent dynamics of the intermolecular binding (Fig. 1D). These simulations enabled the quantification of: (i) persistent antibody–antigen contacts, (ii) intra- and intermolecular interaction networks, and (iii) the dynamic inter-domain rearrangements controlling the interfacial binding energy landscape. In addition, a two-dimensional projection of the binding landscape was generated to facilitate visualization of the corresponding contact patterns (Fig. 1E). (Fig. 1E).

The structure of the JAM-A antigen was predicted and subsequently trimmed to retain only the extracellular Ig-like domains, removing residues belonging to flexible regions outside the structured binding interface. Similarly, the antibody was truncated to include only the antigen-binding fragments (Fab), with residues corresponding to the crystallizable fragment (Fc) removed. This preprocessing ensured that the MD simulations focused exclusively on the antibody–antigen recognition interface. By transitioning from sequence to predicted structure and ultimately to MD simulations, this framework reformulates clonal selection as an ensemble-based problem. Rather than ranking clones by static binding parameters, our approach quantifies how each antibody explores conformational space and establishes distinct contact topologies with JAM-A, providing a mechanistic basis for predicting differential internalization behavior.

B. Binding free energy evaluation to predict mAB internalization

To quantitatively evaluate the thermodynamic landscape governing antibody–antigen recognition, we performed Umbrella Sampling simulations for five anti–JAM-A clones (4F12, 5G11, 25C7, 25F9, and 22G6). For each clone, the Fab was simulated at increasing separation distances from the ectodomain of JAM-A, and the resulting trajectories were used to reconstruct the potential of mean force (PMF) profile (Fig. 2A). The reconstructed free-energy profiles reveal substantially different binding pathways among clones. Although all complexes exhibit a defined energetic minimum corresponding to the bound state, the depth, curvature, and width of the PMF profiles differ markedly. Clones displaying the deepest energy well do not necessarily follow identical association/dissociation pathways, indicating that binding strength alone does not capture the full complexity of the binding stabilization mechanisms.

From the PMF profiles, we derived binding free-energy estimates that enabled quantitative scoring of each clone (Fig. 2B). To further dissect the molecular determinants underlying these binding affinity differences, we analyzed the intermolecular contact frequencies through a distance cut-off analysis[34] between the antibodies and JAM-A residues exhibiting the lowest- and highest-affinity, i.e., 25C7 and 4F12 clones, respectively. The resulting contact maps (Fig. 2C–D) reveal pronounced differences in the interaction patterns established between the Fab light chains and the JAM-A receptor. In particular, contacts involving the variable region of the light chain (LC:1–109) displayed markedly different distributions along the JAM-A sequence. Two major regions of the antigen can be distinguished (JAM-A:1–100 and JAM-A:101–211), where the overall contact density decreases for the high-affinity clone and reorganizes into a distinct interaction landscape for to the lowest-affinity clone. Beyond these structural differences, analysis of interaction types revealed a striking shift in the physicochemical nature of the antibody–antigen interface. For the 25C7 clone, the contact maps show a dominant interaction type of hydrophobic-driven intermolecular contacts (Fig. 2C-right), complemented by a heterogeneous network of contacts enriched in cation-π interactions and polar residues. In contrast, the interaction pattern observed for the 4F12 clone (Fig. 2D-right) is characterized by a clear enrichment of polar contacts and electrostatically-driven interactions, indicating a more specific and localized stabilization of the binding interface.

To quantify the energetic contribution of individual



FIG. 1. Structural and computational framework of the anti–JAM-A antibody system. A. Amino acid sequences of the monoclonal antibody heavy and light chains together with the target antigen JAM-A. Residues are color-coded according to physicochemical class, as indicated in the legend, highlighting the distribution of polar, charged, hydrophobic, and special-function amino acids across antibody and antigen sequences. B. Predicted molecular models obtained using ColabFold[27–31]. Left: antibody structure; right: JAM-A ectodomain. Structures are colored according to per-residue predicted Local Distance Difference Test (pLDDT) confidence scores, with the color gradient indicating model reliability at atomic resolution. C. Identification of complementarity-determining regions (CDRs). The three heavy-chain CDRs are shown in blue and the three light-chain CDRs in red. The predicted antigen-binding interface is displayed in green, illustrating the spatial convergence of CDR loops toward the epitope region. D. Global view of the simulated system. The antibody is shown with its two heavy chains (blue and cyan) and two light chains (red and orange) in complex with two JAM-A molecules (green). The full assembly represents the starting configuration for membrane-resolved molecular dynamics simulations. E. Binding interaction landscape of the antibody–antigen complex. The upper panel shows the interaction energy surface, whereas the lower panel displays its two-dimensional projection, which facilitates visualization of the corresponding contact maps. Blue, red, and green boxes highlight representative intramolecular interactions between antibody heavy chains, antibody light chains, and antigen–antigen contacts, respectively.

contacts, we calculated pairwise interaction energies for the ten most favorable residue pairs at the interface

(Fig. 2E–F). For the 25C7 clone, the strongest interaction corresponds to a polar contact between serine and glutamic acid, followed by cation-π contacts such as arginine-tyrosine and arginine-tryptophan, as well as polar-like contacts mediated by serine, threonine, asparagine and glycine. For the 4F12 clone, the strongest interaction corresponds to an electrostatic contact between arginine and glutamic acid. Additional energetic contacts are mediated by residues including tyrosine, serine, asparagine and glycine. The differences between the most energetic contact pairs and their location across the sequence for each clone highlight the presence of concentrated binding hotspots which modulate the global binding free energy as well as the binding association pathway between the CDRs and the epitope.

To experimentally evaluate antibody internalization, we performed immunofluorescence assays in ovarian cancer cells (OVCAR-3) using the different mAb clones (Fig. 3). Cells were treated with the antibodies for 0 and 12 hours, as described in the Materials and Methods section. As shown in Fig. 3A, the clones displaying clear internalization after 12 hours were 5G11 and 4F12, consistent with the computational predictions exhibiting lower binding free energy. Remarkably at 0 hours the strongest membrane-associated signal was observed for clones 25F9, 25C7, and 22G6, which also matches those with the highest calculated binding affinities (Fig. 2B). Internalization percentages were quantified as described in the Materials and Methods section. As shown in Fig. 3B, clones 4F12 and 5G11 exhibit significantly higher internalization levels than clones 25F9, 25C7, and 22G6. In this panel, the internalization percentages are compared against the binding free energies obtain in simulations, highlighting a well-defined energetic regime associated with internalization between binding interactions and cellular uptake Notably, clones with the lowest calculated free energies—reflecting the highest predicted affinities—did not correlate with productive cellular uptake. This observation suggests the existence of an optimal binding interaction energy range for internalization. Excessively strong binding may kinetically stabilize receptor engagement, potentially limiting the dynamic rearrangements required for receptor clustering and endocytosis, whereas moderate and multivalent binding energies may allow sufficient conformational plasticity to enable productive intracellular trafficking.

C. Mechanistic analysis of multivalent binding modes and antibody internalization

Next, we studied a humanized antibody derived from the rabbit clone 4F12 and investigated the mechanistic basis of its internalization. Although JAM-A is overexpressed in ovarian tumor cells, it normally functions as a tight-junction protein, with its spatial organization tightly regulated in epithelial tissues[35]. In tumor cells, disruption of this architecture leads to a more heterogeneous distribution of JAM-A across the plasma membrane, which can limit the local receptor density accessible to antibodies[36]. Given this heterogeneous distribution, the mode of antibody engagement—whether monovalent or bivalent—may critically influence internalization. We explored possible modes of engagement by considering the stoichiometry of binding: i) a monovalent interaction involving one Fab and one JAM-A receptor (1 Fab–1 receptor), ii) a partially bivalent complex in which both Fab domains are present but only one receptor is engaged (2 Fab–1 receptor), and iii) a fully bivalent complex engaging both Fab domains with two receptors (2 Fab–2 receptor). To dissect the internalization mechanism of the humanized 4F12 antibody, we analyzed the binding energetics associated with each stoichiometric scenario. Binding free energies were estimated using umbrella sampling simulations, and PMFs (Fig. 4B) were reconstructed along a normalized reaction coordinate, with 0 representing maximum contact and 1 representing distances at which their interaction vanishes into zero. Such normalization allowed direct comparison between the different binding modes despite variations in absolute center-of-mass distances.

To dissect the internalization mechanism of the humanized 4F12 antibody, we analyzed the binding energetics (Fig. 4C) and residue-residue interactions of the three principal binding modes (Fig. 4D–J). The initial recognition mode (mode I: 1 Fab–1 receptor) exhibits a moderate binding free energy of approximately 23 kJ mol^{-1}. The subsequent interaction mode (mode II: 2 Fab–1 receptor) shows a similar energy of 20 kJ mol^{-1}, suggesting that these two binding modes may coexist in a highly dynamic equilibrium across lateral diffusion over the cell surface. This multivalent binding mode may allow the antibody–receptor complex to diffuse and efficiently encounter a second JAM-A receptor, ultimately enabling bivalent engagement.

Analysis of the contact maps highlights the multivalent behavior of the antibody. In mode II, each Fab engages a distinct Ig-like domain of the single JAM-A antigen, preventing symmetric contacts. In contrast, the fully bivalent 2:2 mode shows increased avidity and partially symmetric cooperative interactions. The first JAM-A antigen primarily engages the variable region of the heavy chain of Fab 1, with weaker interactions to Fab 2, while also engaging the variable region of the light chain of Fab 2. The second JAM-A antigen interacts strongly with the light chain of Fab 2 and with the constant region of the heavy chain of Fab 1. Contacts with the light chain of Fab 1 are weaker, but overall the pattern demonstrates symmetry across the two Fab domains (Fig. 4D-F). Additionally, the two JAM-A antigens interact via their first Ig-like domains, further stabilizing the multivalent complex (Fig. 4F; inset). These maps illustrate how multivalency distributes binding across multiple interfaces, enhancing avidity and stabilizing the fully engaged complex.

Once the second receptor is engaged, the system



FIG. 2. Free-energy landscapes and interfacial interaction patterns discriminate antibody clones. A) Potentials of mean force (PMFs) obtained from umbrella sampling simulations for the five antibody clones. The reaction coordinate corresponds to the center-of-mass distance between the Fab fragment and the JAM-A antigen. Representative simulation snapshots illustrating the associated (bound) and dissociated states of the complex are shown above the profiles. B. Binding free energies extracted from the PMFs for each clone and ranked from lowest to highest affinity. C–D. Intermolecular contact maps for the clones 25C7 (C) and 4F12 (D). For each clone, the left panels show the contact frequency between antibody and antigen residues, while the right panels classify contacts according to their interaction type. Differences are particularly evident in the interaction patterns involving the variable region of the Fab light chain and distinct regions of the JAM-A receptor. E–F. Pairwise interaction energies for the ten most favorable intermolecular residue pairs at the antibody–antigen interface for clones 25C7 (E) and 4F12 (F), highlighting the emergence of dominant energetic hotspots in the high-affinity clone compared with the more distributed interaction network observed in 25C7.

reaches the fully bivalent "internalization binding mode" (mode III: 2 Fab–2 receptor), forming a trimeric complex composed of two JAM-A antigens and one antibody. This state exhibits a substantially higher binding free energy of 58 kJ mol^{-1}, stabilizing the complex at the membrane and enabling the initiation of membrane curvature required for early endocytosis. The high affinity is mechanistically necessary, as bending the membrane incurs an energetic penalty proportional to the bending modulus and interfacial rigidity, reflecting the excess area generated during curvature. To validate these computational predictions, we also performed surface plasmon resonance (SPR) experiments of the humanized 4F12 clone to measure the antibody's affinity for JAM-A. Remarkably, the experimental SPR value (51 kJ mol^{-1}; Fig. 4C) near-quantitatively matches the simulation prediction, reinforcing the hypothesis that the 2:2 complex represents the energetically preferred and functionally relevant binding mode. By achieving sufficient interaction energy, the antibody–receptor complex can overcome the mechanical cost of membrane curvature, effectively anchoring to the membrane and promoting early endocytosis. A schematic representation of this multi-step internalization mechanism is shown in Fig. 4K.

III. CONCLUSIONS

In this study, we combined protein structural prediction, MD simulations, and *in vitro* cell-based immunofluorescence experiments to dissect the molecular determinants of antibody internalization in tumor cells. Using antibodies targeting JAM-A, a tight-junction-associated receptor dysregulated in epithelial malignancies, we demonstrated that moderate binding energies (i.e., between 20-30 kJ/mol) between one Fab domain and one receptor correlate with productive cellular uptake. Our all-atom PMF calculations, contact map analyses and energetic decomposition, combined with immunofluorescence assays suggest that moderate binding affinities enable dynamic exploration of the cell surface, facilitating further engagement with two receptors in a multivalent manner. Such stable engagement ultimately drives intracellular uptake.

Our fully humanized 4F12 antibody exhibits a hierarchy of binding modes, from initial recognition (1 Fab–1 receptor) to a bivalent, high-affinity internalization binding mode. Contact maps show that multivalency distributes interactions across multiple sequence interfaces, including antibody–antigen and antigen–antigen con-



FIG. 3. A. Evaluation of the internalization of the five monoclonal antibodies against the JAM-A protein. Treatments were carried out for 0 hours (30 minutes of incubation with each antibody at 37ºC followed by fixation) and 12 hours (treatment for 30 minutes, following by washing and incubation for 12 hours at 37ºC). White arrows indicate intracellular accumulations of the antibody signal. Inmunofluorescence was then performed as indicated in methods. Images were taken using a Nikon Eclipse E200 inverted fluorescence microscope and processed using ImageJ software. Computed binding free energy plotted as a function of the experimentally measured percentage of antibody internalization. Each point represents an antibody variant. Shaded regions red and green indicate energetic internalization regimes incompatible or compatible respectively.

tacts, enhancing avidity and stabilizing the fully engaged complex. The high binding energy—evaluated through PMF calculations and SPR in vitro experiments—of the internalization mode (e.g., of 50-60 kJ/mol) is mechanistically required to overcome the energetic cost of membrane bending during pre-endosome formation, linking molecular recognition directly to cellular mechanics. This framework highlights a mechanistic principle for antibody design that is well-characterized in other contexts but largely unexplored in ADC development[11]: achieving an optimal balance between affinity, multivalency, and dynamic receptor engagement is critical for efficient internalization. Excessive affinity in the initial recognition step may impede receptor search, dynamic orientational rearrangements to find the optimal pose, and limit productive uptake. In contrast, moderate binding affinities maintain dynamic attachment, thereby facilitating the formation of multivalent complexes formed by two receptors and one antibody, capable of anchoring and deforming the membrane.

Our integrated computational-experimental approach provides a quantitative platform for clonal selection and antibody engineering, enabling the identification of candidates that combine favorable binding energetics with significant internalization kinetics. Beyond JAM-A, this strategy is broadly applicable to the rational design of antibodies and ADCs against cell-surface receptors where internalization and receptor clustering are essential for therapeutic efficacy. In conclusion, our results define a principled pathway from sequence to mechanism, demonstrating that molecular dynamics-informed clonal selection can guide the design of antibodies with optimal cel-



FIG. 4. Mechanistic characterization of humanized 4F12 binding and internalization. A. Structural visualization of the three predicted binding modes I: 1:1, II: 2:1 and III: 2:2. The JAM-A antigen(s) are shown in green, while the antibody heavy and light chains are depicted in blue and red, respectively. B. PMFs computed for the three binding modes. C. Quantitative scoring of each mode based on ΔG extracted from PMFs, compared with experimental SPR measurements. D–F. Residue-residue contact maps for modes I, II, and III, respectively; F inset highlights contacts between the two JAM-A antigens in the III mode. G–J. Interaction energies of the ten most stabilizing residue pairs for modes I, II, and III, respectively. K. Schematic representation of the proposed internalization mechanism, illustrating the three binding modes and the antibody (red) sequential engagement with JAM-A receptors (blue) leading to membrane anchoring and pre-endosome formation.

lular uptake. Thus, this study establishes a generalizable methodology for rational engineering of next-generation antibody therapeutics.

IV. METHODS

Simulation details. The JAM-A antigen structure was predicted using ColabFold[27–31] and cut to retain only the extracellular Ig-like domains, removing flexible residues outside of the structured binding regions. The antibody was truncated to its Fab fragment, with Fc residues removed, ensuring that the simulations focused exclusively on the recognition interface. The Systems were solvated with TIP3P water and neutralized with counterions, followed by energy minimization. All simulations were performed in GROMACS[37] with the AMBER99SB-ILDN force field[33]. Electrostatics were treated with PME[38] and a 1.4 nm cutoff and van der Waals interactions were truncated at the same distance. Temperature and pressure were maintained at 298 K and 1 bar using a velocity-rescale[39] thermostat and a C-rescale[40] barostat. Steered molecular dynamics (SMD) was applied to generate initial unbinding pathways. A harmonic pulling potential (k = 1000 kJ mol^{-}1 nm^{-}2) was applied along the center-of-mass reaction coordinate at 0.01 nm ps^{-}1. Umbrella sampling[41–43] was performed along the normalized reaction coordinate (0 = close contact to 1 maximal separation), the resulting histograms of the restricted positions were analyzed using the Weighted Histogram Analysis Method[44] (WHAM) to reconstruct the potential of mean force (PMF). Mode I (1 Fab–1 receptor) used 13 windows, mode II (2 Fab–1 receptor) 27 windows, and mode III (2 Fab–2 receptor) 34 windows, with 5 ns of production per window. Statistical uncertainties were estimated using a bootstrap analysis, in which time correlations were explicitly accounted for by evaluating the integrated autocorrelation time of the reaction coordinate in each window Residue-residue contacts were computed between Cα atoms with a cutoff of 2.5 nm and analyzed for frequency and interaction type (polar, nonpolar, electrostatic). Pairwise interaction energies were calculated for the ten most stabilizing residue pairs per mode, identifying energetic hotspots and allowing correlation between interfacial architecture, computed binding affinities, and experimental observations.

Experimental details. An ovarian cancer cell line was seeded on glass coverslips and, after 24 hours, treated with each monoclonal antibody (10 nM) for the indicated times, consisting of 30 minutes of antibody incubation at 37°C, followed by fixation for time 0, or washing and incubation for 12 hours. The coverslips were then washed and fixed in 2% paraformaldehyde for 30 minutes at room temperature. The coverslips were then washed and incubated with a quenching solution (NH_4Cl) in PBS +/+. For permeabilization, they were rinsed with PBS +/+ containing 0.1% Triton X-100 and 0.2% BSA for 10 minutes three times and washed with PBS +/+ containing 0.2% BSA . All chemicals were purchased from Sigma Aldrich (St. Louis, MO). The coverslips were then incubated with anti-rabbit Cy3 (1:750, Thermofisher Scientific, USA) for 30 minutes. Hoechst 33342 (1:10,000, MedChemExpress, Monmouth Junction, NJ, USA) was added and washed with PBS +/+. The mounting medium was FluorSave™ reagent (Merck, Darmstadt, Germany). Fluorescence images of the cells were obtained using a Nikon Eclipse E200 inverted fluorescence microscope and analyzed using ImageJ. The internalization percentage was calculated by counting the cells with internalised JAM-A from a total of 150–200 nuclei per condition.

[1] S. Zinn, R. Vazquez-Lombardi, C. Zimmermann, P. Sapra, L. Jermutus, and D. Christ, "Advances in antibody-based therapy in oncology," *Nature Cancer*, vol. 4, pp. 165–180, Feb 2023.

[2] A. López de Sá, C. Díaz-Tejeiro, E. Poyatos-Racionero, C. Nieto-Jiménez, L. Paniagua Herranz, A. Sanvicente, E. Calvo, P. Pérez-Segura, V. Moreno, F. Moris, and A. Ocana, "Considerations for the design of antibody drug conjugates (adcs) for clinical development: lessons learned," *Journal of Hematology & Oncology*, vol. 16, p. 118, Dec 2023.

[3] C. Nieto-Jiménez, A. Sanvicente, C. Díaz-Tejeiro, V. Moreno, A. lopez de Sá, E. Calvo, J. Martínez-López, P. Pérez-Segura, and A. Ocana, "Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates," *Clinical and Translational Medicine*, vol. 13, no. 9, p. e1329, 2023.

[4] E. R. Boghaert, M. C. Cox, and K. S. Vaidya, "Pathophysiologic and pharmacologic considerations to improve the design and application of antibody? @ sdrug conjugates," *Cancer Research*, vol. 82, pp. 1858–1869, 05 2022.

[5] E. Díaz-Rodríguez, L. Gandullo-Sánchez, A. Ocana, and A. Pandiella, "Novel adcs and strategies to overcome resistance to anti-her2 adcs," *Cancers*, vol. 14, no. 1, 2022.

[6] A. Ocaña, E. Amir, and A. Pandiella, "Her2 heterogeneity and resistance to anti-her2 antibody-drug conjugates," *Breast Cancer Research*, vol. 22, p. 15, Jan 2020.

[7] S. García-Alonso, A. Ocana, and A. Pandiella, "Trastuzumab emtansine: Mechanisms of action and resistance, clinical progress, and beyond," *Trends in Cancer*, vol. 6, no. 2, pp. 130–146, 2020.

[8] A. Passaro, P. A. Jänne, and S. Peters, "Antibody-drug conjugates in lung cancer: Recent advances and implementing strategies," *Journal of Clinical Oncology*, vol. 41, no. 21, pp. 3747–3761, 2023. PMID: 37224424.

[9] A. Beck, L. Goetsch, C. Dumontet, and N. Corvaïa, "Strategies and challenges for the next generation of antibody-drug conjugates," *Nature Reviews Drug Discovery*, vol. 16, pp. 315–337, May 2017.

[10] J. R. McCombs and S. C. Owen, "Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry," *The AAPS Journal*, vol. 17, pp. 339–351, Mar 2015.

[11] S. C. Oostindie, G. A. Lazar, J. Schuurman, and P. W. H. I. Parren, "Avidity in antibody effector functions and biotherapeutic drug design," *Nature Reviews Drug Discovery*, vol. 21, pp. 715–735, Oct 2022.

[12] A. Sorkin and L. K. Goh, "Endocytosis and intracellular trafficking of erbbs," *Experimental Cell Research*, vol. 315, no. 4, pp. 683–696, 2009. Invited Reviews: ErbB Receptors.

[13] G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blättler, J. M. Lambert, R. V. Chari, R. J. Lutz, W. L. T. Wong, F. S. Jacobson, H. Koeppen, R. H. Schwall, S. R. Kenkare-Mitra, S. D. Spencer, and M. X. Sliwkowski, "Targeting her2-positive breast cancer with trastuzumab-dm1, an antibody? @ scytotoxic drug conjugate," *Cancer Research*, vol. 68, pp. 9280–9290, 11 2008.

[14] Y. Ogitani, T. Aida, K. Hagihara, J. Yamaguchi, C. Ishii,

N. Harada, M. Soma, H. Okamoto, M. Oitate, S. Arakawa, T. Hirai, R. Atsumi, T. Nakada, I. Hayakawa, Y. Abe, and T. Agatsuma, "Ds-8201a, a novel her2-targeting adc with a novel dna topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from t-dm1," *Clinical Cancer Research*, vol. 22, pp. 5097–5108, 10 2016.

[15] T. M. Cardillo, S. V. Govindan, R. M. Sharkey, P. Trisal, R. Arrojo, D. Liu, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg, "Sacituzumab govitecan (immu-132), an anti-trop-2/sn-38 antibody–drug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers," *Bioconjugate Chemistry*, vol. 26, no. 5, pp. 919–931, 2015. PMID: 25915780.

[16] J. J. Rhoden, G. L. Dyas, and V. J. Wroblewski, "A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets *," *Journal of Biological Chemistry*, vol. 291, pp. 11337–11347, May 2016.

[17] M. Hammood, A. W. Craig, and J. V. Leyton, "Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (adcs)—a necessity for future adc research and development," *Pharmaceuticals*, vol. 14, no. 7, 2021.

[18] P. R. Moody, E. J. Sayers, J. P. Magnusson, C. Alexander, P. Borri, P. Watson, and A. T. Jones, "Receptor crosslinking: A general method to trigger internalization and lysosomal targeting of therapeutic receptor:ligand complexes," *Molecular Therapy*, vol. 23, no. 12, pp. 1888–1898, 2015.

[19] A. Sorkin and M. von Zastrow, "Endocytosis and signalling: intertwining molecular networks," *Nature Reviews Molecular Cell Biology*, vol. 10, pp. 609–622, Sep 2009.

[20] K. H. Roux, L. Strelets, and T. E. Michaelsen, "Flexibility of human igg subclasses," *The Journal of Immunology*, vol. 159, pp. 3372–3382, 10 1997.

[21] J. P. Brandt, T. W. Patapoff, and S. R. Aragon, "Construction, md simulation, and hydrodynamic validation of an all-atom model of a monoclonal igg antibody," *Biophysical Journal*, vol. 99, no. 3, pp. 905–913, 2010.

[22] P. Strop, K. Delaria, D. Foletti, J. M. Witt, A. Hasa-Moreno, K. Poulsen, M. G. Casas, M. Dorywalska, S. Farias, A. Pios, V. Lui, R. Dushin, D. Zhou, T. Navaratnam, T.-T. Tran, J. Sutton, K. C. Lindquist, B. Han, S.-H. Liu, D. L. Shelton, J. Pons, and A. Rajpal, "Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading," *Nature Biotechnology*, vol. 33, pp. 694–696, Jul 2015.

[23] R. P. Lyon, T. D. Bovee, S. O. Doronina, P. J. Burke, J. H. Hunter, H. D. Neff-LaFord, M. Jonas, M. E. Anderson, J. R. Setter, and P. D. Senter, "Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index," *Nature Biotechnology*, vol. 33, pp. 733–735, Jul 2015.

[24] A. Croitoru, A. A. Orr, and A. D. MacKerell, "Harnessing computational technologies to facilitate antibody?˜@˜sdrug conjugate development," *Nature Chemical Biology*, vol. 21, pp. 1138–1147, Aug 2025.

[25] T. M. Prass, K. Lindorff-Larsen, P. Garidel, M. Blech, and L. V. Schäfer, "Optimized protein–excipient interactions in the martini 3 force field," *Journal of Chemical Information and Modeling*, vol. 65, no. 7, pp. 3581–3592, 2025. PMID: 40129029.

[26] A. R. Tejedor, A. Aguirre Gonzalez, M. J. Maristany, P. Y. Chew, K. Russell, J. Ramirez, J. R. Espinosa, and R. Collepardo-Guevara, "Chemically informed coarse-graining of electrostatic forces in charge-rich biomolecular condensates," *ACS Central Science*, vol. 11, no. 2, pp. 302–321, 2025.

[27] P. Eastman, J. Swails, J. D. Chodera, R. T. McGibbon, Y. Zhao, K. A. Beauchamp, L.-P. Wang, A. C. Simmonett, M. P. Harrigan, C. D. Stern, R. P. Wiewiora, B. R. Brooks, and V. S. Pande, "OpenMM 7: Rapid development of high performance algorithms for molecular dynamics," *PLOS Comput. Biol.*, vol. 13, no. 7, 2017.

[28] M. Mirdita, L. von den Driesch, C. Galiez, M. J. Martin, J. S"oding, and M. Steinegger, "Uniclust databases of clustered and deeply annotated protein sequences and alignments," *Nucleic Acids Res.*, vol. 45, no. D1, pp. D170–D176, 2017.

[29] M. Mirdita, M. Steinegger, and J. S"oding, "MMseqs2 desktop and local web server app for fast, interactive sequence searches," *Bioinformatics*, vol. 35, no. 16, pp. 2856–2858, 2019.

[30] A. L. Mitchell, A. Almeida, M. Beracochea, M. Boland, J. Burgin, G. Cochrane, M. R. Crusoe, V. Kale, S. C. Potter, L. J. Richardson, E. Sakharova, M. Scheremetjew, A. Korobeynikov, A. Shlemov, O. Kunyavskaya, A. Lapidus, and R. D. Finn, "MGnify: the microbiome analysis resource in 2020," *Nucleic Acids Res.*, 2019.

[31] M. Mirdita, K. Schütze, Y. Moriwaki, L. Heo, S. Ovchinnikov, and M. Steinegger, "Colabfold: making protein folding accessible to all," *Nature Methods*, vol. 19, pp. 679–682, Jun 2022.

[32] S. Blazquez, I. Sanchez-Burgos, J. Ramirez, T. Higginbotham, M. M. Conde, R. Collepardo-Guevara, A. R. Tejedor, and J. R. Espinosa, "Location and concentration of aromatic-rich segments dictates the percolating inter-molecular network and viscoelastic properties of ageing condensates," *Advanced Science*, vol. 10, no. 25, p. 2207742, 2023.

[33] K. Lindorff-Larsen, S. Piana, K. Palmo, P. Maragakis, J. L. Klepeis, R. O. Dror, and D. E. Shaw, "Improved side-chain torsion potentials for the amber ff99sb protein force field," *Proteins: Structure, Function, and Bioinformatics*, vol. 78, no. 8, pp. 1950–1958, 2010.

[34] A. R. Tejedor, A. Garaizar, J. Ramírez, and J. R. Espinosa, "'rna modulation of transport properties and stability in phase-separated condensates," *Biophysical Journal*, vol. 120, no. 23, pp. 5169–5186, 2021.

[35] I. Martìn-Padura, S. Lostaglio, M. Schneemann, L. Williams, M. Romano, P. Fruscella, C. Panzeri, A. Stoppacciaro, L. Ruco, A. Villa, D. Simmons, and E. Dejana, "Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration," *Journal of Cell Biology*, vol. 142, pp. 117–127, 07 1998.

[36] A. Lauko, Z. Mu, D. H. Gutmann, U. P. Naik, and J. D. Lathia, "Junctional adhesion molecules in cancer: A paradigm for the diverse functions of cell-cell interactions in tumor progression," *Cancer Research*, vol. 80, pp. 4878–4885, 11 2020.

[37] D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. C. Berendsen, "Gromacs: Fast, flexible, and free," *Journal of Computational Chemistry*, vol. 26, no. 16, pp. 1701–1718, 2005.

[38] T. Darden, D. York, and L. Pedersen, "Particle mesh Ewald: An n log(n) method for Ewald sums in large systems," *The Journal of Chemical Physics*, vol. 98, pp. 10089–10092, 06 1993.

[39] G. Bussi, D. Donadio, and M. Parrinello, "Canonical sampling through velocity rescaling," *The Journal of Chemical Physics*, vol. 126, p. 014101, 01 2007.

[40] M. Bernetti and G. Bussi, "Pressure control using stochastic cell rescaling," *The Journal of Chemical Physics*, vol. 153, p. 114107, 09 2020.

[41] G. Patey and J. Valleau, "The free energy of spheres with dipoles: Monte carlo with multistage sampling," *Chemical Physics Letters*, vol. 21, no. 2, pp. 297–300, 1973.

[42] G. M. Torrie and J. P. Valleau, "Monte carlo free energy estimates using non-boltzmann sampling: Application to the subcritical lennard-jones fluid," *Chemical Physics Letters*, vol. 28, no. 4, pp. 578–581, 1974.

[43] G. Torrie and J. Valleau, "Nonphysical sampling distributions in monte carlo free-energy estimation: Umbrella sampling," *Journal of Computational Physics*, vol. 23, no. 2, pp. 187–199, 1977.

[44] S. Kumar, J. M. Rosenberg, D. Bouzida, R. H. Swendsen, and P. A. Kollman, "The weighted histogram analysis method for free-energy calculations on biomolecules. i. the method," *Journal of Computational Chemistry*, vol. 13, no. 8, pp. 1011–1021, 1992.

V. ACKNOWLEDGEMENTS

P.L acknowledges funding from the European Union's Horizon 2020 research and innovation program (grant agreement 101160499 to J. R. E). J. R. E. acknowledges funding from Emmanuel College, the University of Cambridge, the Ramón y Cajal fellowship (RYC2021-030937-I), the Spanish scientific plan and committee for research reference PID2022-136919NA-C33, and the European Research Council (ERC) under the European Union's Horizon Europe research and innovation program (grant agreement no. 101160499). C.N.J and A.O., acknowledge funding from CRIS Cancer Foundation (AOF.C01CRIS and AOF.M01CRIS).

VI. COMPETING INTERESTS STATEMENT

The authors declare no competing interests